Chagas disease in the immunocompromised host.

Journal

Current opinion in infectious diseases

ISSN: 1473-6527

Titre abrégé: Curr Opin Infect Dis

Pays: United States

ID NLM: 8809878

Informations de publication

Date de publication:
05 Jul 2024

Historique:

medline: 4 7 2024

pubmed: 4 7 2024

entrez: 4 7 2024

Statut: aheadofprint

Résumé

To highlight recent advances in our understanding of Trypanosoma cruzi infection in immunocompromised individuals, a condition that is increasingly recognized as populations shift and use of immunosuppressive medications becomes more commonplace. Chagas disease screening programs should include people at risk for both Chagas disease and immunocompromise, e.g. people who have resided for ≥6 months in endemic Latin America who have an immunocompromising condition such as HIV or who are planned to start an immunosuppressive medication regimen. The goal of identifying such individuals is to allow management strategies that will reduce their risk of T. cruzi reactivation disease. For people with HIV-T. cruzi coinfection, strict adherence to antiretroviral therapy is important and antitrypanosomal treatment is urgent in the setting of symptomatic reactivation. People at risk for T. cruzi reactivation due to immunosuppression caused by advanced hematologic conditions or postsolid organ transplantation should be monitored via T. cruzi qPCR and treated with preemptive antitrypanosomal therapy if rising parasite load on serial specimens indicates reactivation. Reduction of the immunosuppressive regimen, if possible, is important. Chronic Chagas disease can lead to severe disease in immunocompromised individuals, particularly those with advanced HIV (CD4+ < 200 cells/mm3) or peri-transplantation.

Identifiants

DOI: 10.1097/QCO.0000000000001035 PMID: 38963802

pubmed: 38963802

doi: 10.1097/QCO.0000000000001035

pii: 00001432-990000000-00157

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Tarleton RL. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 2007; 19:430–434.

Lidani KCF, Bavia L, Ambrosio AR, de Messias-Reason IJ. The complement system: a prey of Trypanosoma cruzi. Front Microbiol 2017; 8:607.

Dutra WO, Menezes CA, Villani FN, et al. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 2009; 104: (Suppl 1): 208–218.

Kumar S, Tarleton RL. The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol 1998; 20:207–216.

Almeida EA, Mendes F, Ramos Junior AN, et al. Guidelines for Trypanosoma cruzi-HIV co-infection and other immunosuppressive conditions: diagnosis, treatment, monitoring, and implementation from the International Network of Care and Studies – 2023. Rev Soc Bras Med Trop 2023; 56:0549.

Gray EB, La Hoz RM, Green JS, et al. Reactivation of Chagas disease among heart transplant recipients in the United States. Transpl Infect Dis 2018; 20:e12996.

Freitas VLT, Novaes CTG, Sartori AMC, et al. Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection. PLoS Negl Trop Dis 2024; 18:e0011961.

Clark EH, Marquez C, Whitman JD, Bern C. Screening for Chagas disease should be included in entry-to-care testing for at-risk people with human immunodeficiency virus (HIV) living in the United States. Clin Infect Dis 2022; 75:901–906.

Forsyth CJ, Manne-Goehler J, Bern C, et al. Recommendations for screening and diagnosis of Chagas disease in the United States. J Infect Dis 2022; 225:1601–1610.

Perez-Molina JA, Rodriguez-Guardado A, Soriano A, et al. Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials 2011; 12:287–298.

Guidelines for the diagnosis and treatment of Chagas disease: Pan American Health Organization (PAHO); 2018. Available at: https://iris.paho.org/handle/10665.2/49653.

Benchetrit AG, Fernandez M, Bava AJ, et al. Clinical and epidemiological features of chronic Trypanosoma cruzi infection in patients with HIV/AIDS in Buenos Aires, Argentina. Int J Infect Dis 2018; 67:118–121.

Almeida EA, Ramos Junior AN, Correia D, Shikanai-Yasuda MA. Co-infection Trypanosoma cruzi/HIV: systematic review (1980–2010). Rev Soc Bras Med Trop 2011; 44:762–770.

Almeida EA, Lima JN, Lages-Silva E, et al. Chagas’ disease and HIV co-infection in patients without effective antiretroviral therapy: prevalence, clinical presentation and natural history. Trans R Soc Trop Med Hyg 2010; 104:447–452.

Stauffert D, Silveira MF, Mesenburg MA, et al. Prevalence of Trypanosoma cruzi/HIV coinfection in southern Brazil. Braz J Infect Dis 2017; 21:180–184.

Kesper N, Ignacio Junior JC, Rocci RA, et al. Prevalence of Trypanosoma cruzi infection in a cohort of people living with HIV/AIDS from an urban area. Epidemiol Infect 2023; 151:e72.

Hasslocher-Moreno AM, Sousa AS, Xavier SS, et al. Epidemiological-clinical profile and mortality in patients coinfected with Trypanosoma cruzi/HIV: experience from a Brazilian reference center. Rev Soc Bras Med Trop 2022; 55:e02402022.

Dolcini G, Ambrosioni J, Andreani G, et al. Prevalence of human immunodeficiency virus (HIV)-Trypanosoma cruzi co-infection and injectable-drugs abuse in a Buenos Aires health center. Rev Argent Microbiol 2008; 40:164–166.

Benchetrit A, Andreani G, Avila MM, et al. High HIV-Trypanosoma cruzi coinfection levels in vulnerable populations in Buenos Aires, Argentina. AIDS Res Hum Retroviruses 2017; 33:330–331.

Scapellato PG, Bottaro EG, Scapellato JI, Vidal GI. Can Chagas disease be transmitted by sharing syringes in HIV+ drug addicts? Medicina (B Aires) 2006; 66:595–596.

Reimer-McAtee MJ, Mejia C, Clark T, et al. HIV and Chagas disease: an evaluation of the use of real-time quantitative polymerase chain reaction to measure levels of trypanosoma cruzi parasitemia in HIV patients in Cochabamba, Bolivia. Am J Trop Med Hyg 2021; 105:643–650.

Hochberg NS, Moro RN, Sheth AN, et al. High prevalence of persistent parasitic infections in foreign-born, HIV-infected persons in the United States. PLoS Negl Trop Dis 2011; 5:e1034.

Ahmed N, Herbert S, Arenas-Pinto A, et al. Trypanosoma cruzi screening in people living with HIV in the UK. Int J STD AIDS 2024; 35:71–73.

Hayon J, Lupo S, Poveda C, et al. Adaptation of Chagas disease screening recommendations for a community of at-risk people with HIV living in the United States. Clin Infect Dis 2024; 78:453–456.

Llenas-Garcia J, Hernando A, Fiorante S, et al. Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem. Eur J Clin Microbiol Infect Dis 2012; 31:1991–1997.

Rodriguez-Guardado A, Asensi Alvarez V, Rodriguez Perez M, et al. Screening for Chagas’ disease in HIV-positive immigrants from endemic areas. Epidemiol Infect 2011; 139:539–543.

Salvador F, Molina I, Sulleiro E, et al. Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain. Am J Trop Med Hyg 2013; 88:1196–1202.

Rodari P, Tamarozzi F, Tais S, et al. Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI study. Travel Med Infect Dis 2022; 48:102324.

Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007; 101:31–50.

Sartori AM, Shikanai-Yasuda MA, Amato Neto V, Lopes MH. Follow-up of 18 patients with human immunodeficiency virus infection and chronic Chagas’ disease, with reactivation of Chagas’ disease causing cardiac disease in three patients. Clin Infect Dis 1998; 26:177–179.

de Freitas VL, da Silva SC, Sartori AM, et al. Real-time PCR in HIV/Trypanosoma cruzi coinfection with and without Chagas disease reactivation: association with HIV viral load and CD4 level. PLoS Negl Trop Dis 2011; 5:e1277.

Cordova E, Boschi A, Ambrosioni J, et al. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina. Int J Infect Dis 2008; 12:587–592.

Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9:324–330.

Concetti H, Retegui M, Perez G, Perez H. Chagas’ disease of the cervix uteri in a patient with acquired immunodeficiency syndrome. Hum Pathol 2000; 31:120–122.

Iliovich E, Lopez R, Kum M, Uzandizaga G. Spontaneous chagasic peritonitis in a patient with AIDS. Medicina (B Aires) 1998; 58 (Pt 1):507–508.

Ferreira MS, Nishioka Sde A, Silvestre MT, et al. Reactivation of Chagas’ disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997; 25:1397–1400.

Oelemann W, Velasquez JN, Carnevale S, et al. Intestinal Chagas’ disease in patients with AIDS. AIDS 2000; 14:1072–1073.

Sartori AM, Neto JE, Nunes EV, et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. J Infect Dis 2002; 186:872–875.

Sartori AM, Sotto MN, Braz LM, et al. Reactivation of Chagas disease manifested by skin lesions in a patient with AIDS. Trans R Soc Trop Med Hyg 1999; 93:631–632.

Livramento JA, Machado LR, Spina-Franca A. Cerebrospinal fluid abnormalities in 170 cases of AIDS. Arq Neuropsiquiatr 1989; 47:326–331.

Hernandez C, Cucunuba Z, Parra E, et al. Chagas disease (Trypanosoma cruzi) and HIV co-infection in Colombia. Int J Infect Dis 2014; 26:146–148.

Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450–457.

Qvarnstrom Y, Schijman AG, Veron V, et al. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multitarget real-time PCR approach. PLoS Negl Trop Dis 2012; 6:e1689.

Perez-Ramirez L, Barnabe C, Sartori AM, et al. Clinical analysis and parasite genetic diversity in human immunodeficiency virus/Chagas’ disease coinfections in Brazil. Am J Trop Med Hyg 1999; 61:198–206.

Castro-Sesquen YE, Gilman RH, Mejia C, et al. Use of a Chagas Urine Nanoparticle Test (Chunap) to correlate with parasitemia levels in T. cruzi/HIV Co-infected Patients. PLoS Negl Trop Dis 2016; 10:e0004407.

Wincker P, Telleria J, Bosseno MF, et al. PCR-based diagnosis for Chagas’ disease in Bolivian children living in an active transmission area: comparison with conventional serological and parasitological diagnosis. Parasitology 1997; 114 (Pt 4):367–373.

Marcon GEB, Ferreira JJG, de Almeida EA, et al. Parasite load evaluation by qPCR and blood culture in Chagas disease and HIV co-infected patients under antiretroviral therapy. PLoS Negl Trop Dis 2022; 16:e0010317.

Kirchhoff LV. American trypanosomiasis (Chagas’ disease). Gastroenterol Clin North Am 1996; 25:517–533.

Fernandez ML, Marson ME, Mastrantonio GE, et al. Benznidazole in cerebrospinal fluid: a case series of Chagas disease meningoencephalitis in HIV-positive patients. Antimicrob Agents Chemother 2021; 65:e01922-20.

Lages-Silva E, Ramirez LE, Silva-Vergara ML, Chiari E. Chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome: diagnosis, follow-up, and genetic characterization of Trypanosoma cruzi. Clin Infect Dis 2002; 34:118–123.

Bisio M, Altcheh J, Lattner J, et al. Benznidazole treatment of chagasic encephalitis in pregnant woman with AIDS. Emerg Infect Dis 2013; 19:1490–1492.

Ferreira MS, Borges AS. Some aspects of protozoan infections in immunocompromised patients- a review. Mem Inst Oswaldo Cruz 2002; 97:443–457.

Guidetto B, Tatta M, Latini V, et al. HIV and Chagas disease coinfection, A tractable disease? Open Forum Infect Dis 2019; 6:ofz307.

Fores R, Sanjuan I, Portero F, et al. Chagas disease in a recipient of cord blood transplantation. Bone Marrow Transplant 2007; 39:127–128.

Ison MG, Lebeis TA, Barros N, et al. Case 20-2019: a 52-year-old woman with fever and rash after heart transplantation. N Engl J Med 2019; 380:2564–2573.

Centers for Disease Control and Prevention Chagas disease after organ transplantation--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:210–212.

Jackson Y, Dang T, Schnetzler B, et al. Trypanosoma cruzi fatal reactivation in a heart transplant recipient in Switzerland. J Heart Lung Transplant 2011; 30:484–485.

Chagas’ Disease Argentine Collaborative Transplant Consortium, Casadei D Chagas’ disease and solid organ transplantation. Transplant Proc 2010; 42:3354–3359.

Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Bone Marrow Transplant Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR–10):1–125. CE1-7.

La Hoz RM, Morris MI. Infectious Diseases Community of Practice of the American Society of Transplant Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13546.

Pierrotti LC, Carvalho NB, Amorin JP, et al. Chagas disease recommendations for solid-organ transplant recipients and donors. Transplantation 2018; 102: (2S Suppl 2): S1–S7.

Pinazo MJ, Miranda B, Rodriguez-Villar C, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando) 2011; 25:91–101.

Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg 2001; 71:1833–1838.

Godoy HL, Guerra CM, Viegas RF, et al. Infections in heart transplant recipients in Brazil: the challenge of Chagas’ disease. J Heart Lung Transplant 2010; 29:286–290.

Furquim SR, Galbiati LC, Avila MS, et al. Survival of heart transplant patients with Chagas’ disease under different antiproliferative immunosuppressive regimens. Arq Bras Cardiol 2023; 120:e20230133.

Fiorelli AI, Santos RH, Oliveira JL Jr, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc 2011; 43:220–224.

Fiorelli AI, Stolf NA, Honorato R, et al. Later evolution after cardiac transplantation in Chagas’ disease. Transplant Proc 2005; 37:2793–2798.

Campos SV, Strabelli TM, Amato Neto V, et al. Risk factors for Chagas’ disease reactivation after heart transplantation. J Heart Lung Transplant 2008; 27:597–602.

Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas’ heart disease. Ann Thorac Surg 1996; 61:1727–1733.

Marchiori PE, Alexandre PL, Britto N, et al. Late reactivation of Chagas’ disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy. J Heart Lung Transplant 2007; 26:1091–1096.

Bocchi EA, Bellotti G, Uip D, et al. Long-term follow-up after heart transplantation in Chagas’ disease. Transplant Proc 1993; 25 (Pt 2):1329–1330.

Clark EH, Messenger LA, Whitman JD, Bern C. Chagas disease in immunocompromised patients. Clin Microbiol Rev 2024; 37:e0009923.

Balderramo D, Bonisconti F, Alcaraz A, et al. Chagas disease and liver transplantation: experience in Argentina using real-time quantitative PCR for early detection and treatment. Transpl Infect Dis 2017; 19: doi: 10.1111/tid.12782. [Epub ahead of print].

doi: 10.1111/tid.12782.

Riarte A, Luna C, Sabatiello R, et al. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis 1999; 29:561–567.

Vazquez MC, Riarte A, Pattin M, Lauricella M. Chagas’ disease can be transmitted through kidney transplantation. Transplant Proc 1993; 25:3259–3260.

Vazquez MC, Riarte A, Pattin M, Campanini A. Evolution of chagasic kidney transplant patients. Transplant Proc 1993; 25:3263–3264.

Vazquez MC, Sabbatiello R, Schiavelli R, et al. Chagas disease and transplantation. Transplant Proc 1996; 28:3301–3303.

Biro M, Hill AL, Cardis M, et al. Chagas disease reactivation associated with cutaneous vasculitis in a heart transplant patient. JAAD Case Rep 2023; 42:42–44.

Almeida DR, Carvalho AC, Branco JN, et al. Chagas’ disease reactivation after heart transplantation: efficacy of allopurinol treatment. J Heart Lung Transplant 1996; 15:988–992.

Bestetti RB, Cury PM, Theodoropoulos TA, Villafanha D. Trypanosoma cruzi myocardial infection reactivation presenting as complete atrioventricular block in a Chagas’ heart transplant recipient. Cardiovasc Pathol 2004; 13:323–326.

Pinesi HT, Strabelli TMV, Aiello VD. Case 4/2019-26-year-old man with congenital chagas disease and heart transplantation. Arq Bras Cardiol 2019; 113:286–293.

Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007; 7:1633–1640.

Kransdorf EP, Czer LS, Luthringer DJ, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant 2013; 13:3262–3268.

Hamilton MM, Sciaudone M, Chang PP, et al. Unexpected case of Chagas disease reactivation in endomyocardial biopsy for evaluation of cardiac allograft rejection. Cardiovasc Pathol 2022; 57:107394.

Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis 2014; 27:418–424.

Benvenuti LA, Gutierrez PS, Aiello VD. Myocarditis, histological detection and parasitic load of Trypanosoma cruzi in endomyocardial biopsies presenting with reactivation of Chagas disease after heart transplantation. Transpl Infect Dis 2023; 25:e14185.

Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005; 36:123–129.

La Hoz RM. Transplantation for Chagas’ disease: closing the knowledge gap. Curr Opin Infect Dis 2022; 35:397–403.

Pinazo MJ, Espinosa G, Cortes-Lletget C, et al. Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis 2013; 7:e1965.

Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in transplant working group. Am J Transplant 2011; 11:672–680.

Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant 2013; 13:2418–2425.

Koff A, Malinis M, Delgado S, et al. Under our very eyes. N Engl J Med 2020; 382:952–957.

Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48:1534–1540.

Barcan LA, Smud A, Besuschio SA, et al. Quantitative PCR-based diagnosis and follow-up of chagas disease primary infection after solid organ transplant: a multicentre study. J Infect Dis 2023; 228:1304–1308.

McCormack L, Quinonez E, Goldaracena N, et al. Liver transplantation using Chagas-infected donors in uninfected recipients: a single-center experience without prophylactic therapy. Am J Transplant 2012; 12:2832–2837.

D’Albuquerque LA, Gonzalez AM, Filho HL, et al. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant 2007; 7:680–684.

Souza FF, Castro ESO, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc 2008; 40:875–878.

Silva AE, Silva AC, Faleiros AC, et al. Acute Chagas’ disease in postrenal transplant and treatment with benzonidazole. Ann Diagn Pathol 2010; 14:199–203.

Notice of OPTN Guidance Change: Recognizing Seasonal and Geographically Endemic Infections in Organ Donors: Considerations during Deceased and Living Donor Evaluation Organ Procurement and Transplantation Network (OPTN); 2023. Available at: https://optn.transplant.hrsa.gov/media/q4xfi14u/policy_notice_dtac_endemic_guidance.pdf.

Rivero I, Boris E, Moravenik M, et al. Acute leukomia and Chagas’ disease. 4 cases. Medicina (B Aires) 1975; 35:73–78.

Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas’ myocarditis during therapy of Hodgkin's disease. Trop Geogr Med 1991; 43:228–230.

Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, et al. Reactivation of Chagas’ disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg 2006; 100:74–78.

Perez-Molina JA, Perez AM, Norman FF, et al. Old and new challenges in Chagas disease. Lancet Infect Dis 2015; 15:1347–1356.

Carvalho NB, Freitas VLT, Seguro FS, et al. Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review. Rev Inst Med Trop Sao Paulo 2024; 66:e10.

Corona S, Amanales C, Avaria MA, et al. Chagasic granuloma of the brain in a patient with lymphoblastic leukemia. Rev Med Chil 1988; 116:676–680.

Kohl S, Pickering LK, Frankel LS, Yaeger RG. Reactivation of Chagas’ disease during therapy of acute lymphocytic leukemia. Cancer 1982; 50:827–828.

Simoes MV, Nonino A, Simoes BP, et al. Reagudization of Chagas myocarditis inducing exclusive right ventricular failure. Arq Bras Cardiol 1994; 62:435–437.

Di Lorenzo GA, Pagano MA, Taratuto AL, et al. Chagasic granulomatous encephalitis in immunosuppressed patients. Computed tomography and magnetic resonance imaging findings. J Neuroimaging 1996; 6:94–97.

Salgado PR, Gorski AG, Aleixo AR, de Barros EO. Tumor-like lesion due to Chagas’ disease in a patient with lymphocytic leukemia. Rev Inst Med Trop Sao Paulo 1996; 38:285–288.

Cohen V, Ceballos V, Rodriguez N, et al. Chagas’ disease as a cause of cerebral mass in a patient with lymphoblastic leukemia in remission. Arch Argent Pediatr 2010; 108:134–137.

Vicco MH, Cesar LI, Musacchio HM, et al. Chagas disease reactivation in a patient non-Hodgkin's lymphoma. Rev Clin Esp (Barc) 2014; 214:e83–e85.

Garzon MI, Sanchez AG, Goy MC, et al. Reactivation of Chagas disease in a patient with follicular lymphoma diagnosed by means of quantitative real-time polymerase chain reaction. Open Forum Infect Dis 2015; 2:ofv060.

Ringer A, Ruffino JP, Leiva R, et al. Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response. Clin Rheumatol 2021; 40:2955–2963.

Sanchez AG, Baenas DF, Bonisconti F, et al. Reactivation of Chagas disease in patients with rheumatic autoimmune diseases diagnosed by molecular quantification techniques. J Clin Rheumatol 2021; 27 (8S):S533–S536.

Burgos LG, Ortiz BD, Canese A, et al. Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case. Am J Dermatopathol 2012; 34:e84–e89.

Chang MS, Bae GH, Almazan T, et al. Concurrent Trypanosoma cruzi and cytomegalovirus reactivation in an immunosuppressed patient with limited cutaneous systemic sclerosis. Am J Dermatopathol 2020; doi: 10.1097/DAD.0000000000001842. [Epub ahead of print].

doi: 10.1097/DAD.0000000000001842.

dos Santos-Neto LL, Polcheira MF, Castro C, et al. Trypanosoma cruzi high parasitemia in patient with systemic lupus erythematosus. Rev Soc Bras Med Trop 2003; 36:613–615.

Kaushal M, Shabani S, Cochran EJ, et al. Cerebral trypanosomiasis in an immunocompromised patient: case report and review of the literature. World Neurosurg 2019; 129:225–231.

Navarrete-Dechent C, Majerson D, Torres M, et al. Use of tumor necrosis factor alpha (TNF alpha) antagonists in a patient with psoriasis and Chagas disease. An Bras Dermatol 2015; 90: (Suppl 1): 171–174.

Vacas AS, Gomez-Santana LV, Torre AC, Galimberti RL. Reactivation of Chagas-Mazza disease during treatment with infliximab. An Bras Dermatol 2017; 92:899–900.